• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

The Weekly Roundup: April 11-15


ICYMI, this week we had stories on physician assistants, diverse perspectives in aesthetic medicine, and more.

POLL: Are you having issues with patient adherence to treatment?

Real-World Implications of Dupilumab Treatment in Atopic Dermatitis

An expert dermatologist provides key takeaways and the real-world significance of dupilumab use for the treatment of atopic dermatitis.

LIBERTY AD CHRONOS Study in Atopic Dermatitis

Andrew Blauvelt, MD, MBA, reviews clinical implications from the phase 3 LIBERTY AD CHRONOS study examining the efficacy of dupilumab plus topical corticosteroids in adult patients with moderate to severe atopic dermatitis.

Live from the Revolutionizing Atopic Dermatitis Conference

The Revolutionizing Atopic Dermatitis conference begins with presentations focused on new treatments, data, and more in atopic dermatitis.

Available Atopic Dermatitis Therapies for Pediatric Patients

Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, expands on his AD overview from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is being held from April 9 to 11 in Baltimore, Maryland.

Eczema Global Scorecard: Patients Struggling to Control Symptoms

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research dives into the importance of the results from their recently released study.

On the Radar: Emerging Biologics, Topical Anti-Inflammatories, and Systemic Treatments for AD

Expert panelists discussed the pros, cons, and unknowns of the fast-growing roster of new AD treatments in a session at the 4th Annual Revolutionizing Atopic Dermatitis Conference held April 9 to 11, 2022 in Baltimore, Maryland.

JAK Inhibitors and Lab Monitoring

Experts take a closer look at when to watch, and what to watch for in patients on JAK inhibitors.

Dupilumab's Impact on Quality of Life in Children 6 Months to 5 Years

An abstract presented at the Revolutionizing Atopic Dermatitis conference discussed the impact of treatment with dupilumab on quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.

Virtual Nurse Education in the Treatment, Management of Patients with AD

An abstract presentation at the current Revolutionizing Atopic Dermatitis Conference highlighted using web-based education on AD for nursing students and RNs.

PDE4 Inhibitors and the Treatment Toolbox for AD

What do topical PDE4 inhibitors bring to the treatment toolbox? Which patients are likely to get the most use out of them? Robert Sidbury, MD, MPH, answers these questions and more in this video interview.

Assessing itch in patients

It's a hallmark of atopic dermatitis, but isn't always easy to assess. A presentation at the Revolutionizing Atopic Dermatitis meeting looks at available tools.

Study: Patients with High Accountability Have Better Adherence to AD Treatment

In her talk at the Revolutionizing Atopic Dermatitis Conference, Madison Cook, BS, gives tips on how to increase accountability, common barriers to overcome with patients, and more.

The Burden of Itch for Pediatric Patients and Parents

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research, explores the hidden burdens of itch that many pediatric patients and parents have to deal with on a daily basis. She expanded on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference was held from April 9 to 11 in Baltimore, Maryland.

Adults with Atopic Dermatitis: Prevalence, Comorbidity, and Demographic Data

A RAD conference abstract presentation highlights the demographic, prevalence, and comorbidity data for adults with atopic dermatitis.

Looking to the Future of AD Treatment

Brett King, MD, of Yale School of Medicine, discusses the future of atopic dermatitis treatment.

A Team Approach to Atopic Dermatitis Treatment

Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, California, discusses the importance of recognizing children with more severe atopic disease and a team approach to treatment.

Study: How Can Digital Therapeutic Interventions Improve Symptoms of Atopic Dermatitis?

What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.

Updated AAD Guidelines to Discuss New Therapies, AD Comorbidities

Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, discusses the American Academy of Dermatology's approach to atopic dermatitis management.

Electronic Cigarette Use, Risk of Non-Melanoma Skin Cancer: Is There a Smoking Gun?

While cigarette smoking has decreased in recent years, the use of e-cigarettes has only grown. But what are e-cigarettes associated risks for non-melanoma skin cancer? A recent study aims to find out.

The Hidden Costs of Atopic Dermatitis

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research expands on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is held from April 9 to 11 in Baltimore, Maryland.

Overview on the Updates in the AAD Guidelines for AD

Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, talks about how education of patients is so important, the upcoming parts of the AAD guidelines to look forward to, and more.

Skin Cancer and the Cutaneous Microbiome: Thinking Small May Produce Big Results

The human microbiota and its involvement in human health and disease has been emphasized in recent years. Now, researchers have begun to explore whether a patient’s unique microbiota may influence skin cancer risk and response to therapy.

Diverse Perspectives in Medical Aesthetics Matter More Than Ever

Dermatology Times® invites medical professionals in the dermatology community to speak out on the vital issues facing the specialty.

Report: Transgender and Gender Diverse Youth Have Special Dermatology Needs

The education on how to treat patients with skin issues in this group needs to be expanded so physicians can better treat their patients.

Cost of Copies Prompts a Lawsuit

In this month's Legal Eagle, David J. Goldberg, MD, JD, dives into a case of amount for fees charged for medical records.

Pointers with Dr Portela: Explaining Alopecia

In this week’s Pointers with Dr Portela, the 208SkinDoc highlights alopecia, discussing the different types, and the emotional impact of hair loss.

Study: Acne Care Can Improve Quality of Life

There is a theory that professional acne care can be effective not only in decreasing clinical signs but also in improving quality of life.

2022: Meeting the Challenges of Advanced BCC

Now, with an increasing emphasis on multidisciplinary tumor review boards and heightened expectations for pipeline drugs, physicians have new tools for building treatment plans that may push response rates beyond the 30% range.

Microneedling Misconceptions

“Microneedling has been touted to the consumer as a means to enhance the penetration of moisturizers, vitamins, skin-lightening ingredients, and other cosmeceuticals. Is this enhanced penetration good? It depends.”

Qualified and Nonqualified Retirement Plans: Why Many Dermatologists Should Use Both... but Don’t

“With a traditional QRP [qualified retirement plan], a participant trades today’s tax rates on their contribution for the tax rates in the future, when they withdraw the money from the plan. If rates rise, the QRP might prove not to be a good deal at all.”

Understanding Dupilumab Treatment Response in Atopic Dermatitis

Dr Andrew Blauvelt discusses the relevance of dupilumab treatment response as seen in the LIBERTY AD OLE and LIBERTY AD CHRONOS studies and shares his approaches to improving atopic dermatitis management.

Unmet Needs in Atopic Dermatitis Management

An expert dermatologist provides insight on unmet needs in clinical trial endpoint measurements that would improve the management of atopic dermatitis.

Optimizing the Treatment of Atopic Dermatitis

Andrew Blauvelt, MD, MBA, shares clinical pearls for the management of atopic dermatitis with systemic therapy.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.